Portfolio company
Alladapt Immunotherapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This biopharmaceutical company develops oral immunotherapies for patients with single or multiple food allergies to reduce the severity of allergic reactions.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Tolergyx
This company develops gastrointestinal immunotherapy capsules to treat food allergies in pediatric and adult patients.
Aravax
This clinical-stage pharmaceutical company develops peptide immunotherapies for patients with food allergies, including a lead product for peanut allergy.
Moonlight Therapeutics
This biotechnology company develops microneedle dermal stamps that deliver allergen immunotherapy to patients suffering from peanut and other food allergies.
Desentum
This biopharmaceutical company develops allergen immunotherapy products to treat patients suffering from respiratory and food allergies.
Allegria therapeutics
This company develops therapeutic treatments that modulate mast cell activity for patients suffering from allergic and inflammatory diseases.
Poplar Therapeutics
The company develops anti-immunoglobulin E antibody therapies to treat patients with food allergies and other atopic conditions.
Alerje
Alerje develops an artificial intelligence powered digital health platform for managing food allergy immunotherapy and treatment for patients, families, and allergists.
Alba Therapeutics Corp
This biopharmaceutical company develops oral peptide therapeutics to treat autoimmune and inflammatory conditions, such as celiac disease, for patients with gastrointestinal disorders.
